Arrowstreet Capital Limited Partnership purchased a new stake in Seres Therapeutics Inc (NASDAQ:MCRB) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 14,100 shares of the biotechnology company’s stock, valued at approximately $143,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. California State Teachers Retirement System lifted its stake in Seres Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 400 shares in the last quarter. Parametric Portfolio Associates LLC lifted its stake in Seres Therapeutics by 2.7% in the second quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 580 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Seres Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 2,410 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Seres Therapeutics by 59.6% in the second quarter. New York State Common Retirement Fund now owns 23,300 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 8,699 shares in the last quarter. Finally, Voya Investment Management LLC bought a new position in Seres Therapeutics in the second quarter valued at approximately $114,000. 79.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of MCRB stock traded down $0.40 during trading on Friday, reaching $7.16. The company’s stock had a trading volume of 129,877 shares, compared to its average volume of 158,315. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.15. The firm has a market cap of $291.04, a PE ratio of -3.24 and a beta of 0.51. Seres Therapeutics Inc has a one year low of $6.65 and a one year high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.71) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.02. The business had revenue of $3.06 million for the quarter, compared to analyst estimates of $3.00 million. Seres Therapeutics had a negative net margin of 278.44% and a negative return on equity of 103.46%. equities analysts predict that Seres Therapeutics Inc will post -2.64 earnings per share for the current fiscal year.
A number of research analysts have weighed in on MCRB shares. Zacks Investment Research lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 24th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.00.
TRADEMARK VIOLATION WARNING: “Arrowstreet Capital Limited Partnership Purchases Shares of 14,100 Seres Therapeutics Inc (NASDAQ:MCRB)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/14100-shares-in-seres-therapeutics-inc-mcrb-acquired-by-arrowstreet-capital-limited-partnership.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.